Source comparison
Tesamorelin Growth Hormone Results Timeline: Full Comparison
Week 1–2 +20–35% 0–1% (not significant) None visible; possible mild fluid retention Fasting GH transiently elevated Receptor priming phase—no morphological changes expected Week 4–8 +30–50% sustained 2–5% Waist circumference may decrease 1–2cm HOMA-IR begins d
This comparison does not assign a generated winner or score.
- Week 1–2
- +20–35%
- 0–1% (not significant)
- None visible; possible mild fluid retention
- Fasting GH transiently elevated
- Receptor priming phase—no morphological changes expected
- Week 4–8
- +30–50% sustained
- 2–5%
- Waist circumference may decrease 1–2cm
- HOMA-IR begins declining in responders
- Early enzymatic upregulation; lipolysis initiating
- Week 12
- +40–60%
- 8–12%
- Noticeable abdominal circumference reduction
- Fasting insulin ↓ 10–15%, triglycerides ↓ 8–12%
- Critical decision point—<5% VAT loss suggests non-response
- Week 20–26
- +45–65%
- 12–18% (peak)
- Visible midsection reduction; belt size down 1–2 notches
- HbA1c may improve 0.2–0.4% in pre-diabetic range
- Plateau phase—maximum VAT reduction achieved
- Week 52 (continued dosing)
- +40–55%
- 10–16% maintained
- Sustained midsection reduction
- Metabolic markers stable
- Maintenance phase—effects preserved with daily dosing
- 12 weeks post-discontinuation
- Returns to baseline
- 40–60% regained
- VAT accumulation resumes
- Insulin resistance begins returning
- Rebound effect—benefits not permanent without continued use